Literature DB >> 24020363

Metabolic adaptations of Leishmania donovani in relation to differentiation, drug resistance, and drug pressure.

Maya Berg1, Manu Vanaerschot, Andris Jankevics, Bart Cuypers, Ilse Maes, Sandip Mukherjee, Basudha Khanal, Suman Rijal, Syamal Roy, Fred Opperdoes, Rainer Breitling, Jean-Claude Dujardin.   

Abstract

Antimonial (sodium stibogluconate, SSG) resistance and differentiation have been shown to be closely linked in Leishmania donovani, with SSG-resistant strains showing an increased capacity to generate infectious (metacyclic) forms. This is the first untargeted LC-MS metabolomics study which integrated both phenomena in one experimental design and provided insights into metabolic differences between three clinical L. donovani strains with a similar genetic background but different SSG-susceptibilities. We performed this analysis at different stages during promastigote growth and in the absence or presence of drug pressure. When comparing SSG-resistant and SSG-sensitive strains, a number of metabolic changes appeared to be constitutively present in all growth stages, pointing towards a clear link with SSG-resistance, whereas most metabolic changes were only detected in the stationary stage. These changes reflect the close intertwinement between SSG-resistance and an increased metacyclogenesis in resistant parasites. The metabolic changes suggest that SSG-resistant parasites have (i) an increased capacity for protection against oxidative stress; (ii) a higher fluidity of the plasma membrane; and (iii) a metabolic survival kit to better endure infection. These changes were even more pronounced in a resistant strain kept under Sb(III) drug pressure.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24020363     DOI: 10.1111/mmi.12374

Source DB:  PubMed          Journal:  Mol Microbiol        ISSN: 0950-382X            Impact factor:   3.501


  24 in total

1.  Experimental resistance to drug combinations in Leishmania donovani: metabolic and phenotypic adaptations.

Authors:  Maya Berg; Raquel García-Hernández; Bart Cuypers; Manu Vanaerschot; José I Manzano; José A Poveda; José A Ferragut; Santiago Castanys; Jean-Claude Dujardin; Francisco Gamarro
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

2.  Chronic arsenic exposure and microbial drug resistance.

Authors:  Malcolm J McConville; Stuart A Ralph
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-13       Impact factor: 11.205

Review 3.  Antimony transport mechanisms in resistant leishmania parasites.

Authors:  Frédéric Frézard; Rubens Monte-Neto; Priscila G Reis
Journal:  Biophys Rev       Date:  2014-01-25

4.  Correlation between glucose uptake and membrane potential in Leishmania parasites isolated from DCL patients with therapeutic failure: a proof of concept.

Authors:  Maritza Padrón-Nieves; Claudia Machuca; Emilia Díaz; Paulo Cotrim; Noris Rodriguez; Alicia Ponte-Sucre
Journal:  Parasitol Res       Date:  2014-03-27       Impact factor: 2.289

5.  Genomic Appraisal of the Multifactorial Basis for In Vitro Acquisition of Miltefosine Resistance in Leishmania donovani.

Authors:  P Vacchina; B Norris-Mullins; M A Abengózar; C G Viamontes; J Sarro; M T Stephens; M E Pfrender; L Rivas; M A Morales
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

6.  A Multiplatform Metabolomic Approach to the Basis of Antimonial Action and Resistance in Leishmania infantum.

Authors:  David Rojo; Gisele A B Canuto; Emerson A Castilho-Martins; Marina F M Tavares; Coral Barbas; Ángeles López-Gonzálvez; Luis Rivas
Journal:  PLoS One       Date:  2015-07-10       Impact factor: 3.240

7.  Comparative Fitness of a Parent Leishmania donovani Clinical Isolate and Its Experimentally Derived Paromomycin-Resistant Strain.

Authors:  Sarah Hendrickx; Annelies Leemans; Annelies Mondelaers; Suman Rijal; Basudha Khanal; Jean-Claude Dujardin; Peter Delputte; Paul Cos; Louis Maes
Journal:  PLoS One       Date:  2015-10-15       Impact factor: 3.240

Review 8.  Comparative analysis of the omics technologies used to study antimonial, amphotericin B, and pentamidine resistance in leishmania.

Authors:  Gagandeep Kaur; Bhawana Rajput
Journal:  J Parasitol Res       Date:  2014-05-12

Review 9.  Drug resistance in eukaryotic microorganisms.

Authors:  Alan H Fairlamb; Neil A R Gow; Keith R Matthews; Andrew P Waters
Journal:  Nat Microbiol       Date:  2016-06-24       Impact factor: 17.745

10.  Metabolomic Analyses of Leishmania Reveal Multiple Species Differences and Large Differences in Amino Acid Metabolism.

Authors:  Gareth D Westrop; Roderick A M Williams; Lijie Wang; Tong Zhang; David G Watson; Ana Marta Silva; Graham H Coombs
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.